UNIT 3.13 Assessing Sensitivity to Antibacterial Topoisomerase II Inhibitors

  1. Sonia K. Morgan-Linnell1,
  2. Hiroshi Hiasa2,
  3. Lynn Zechiedrich1,
  4. John L. Nitiss3

Published Online: 1 DEC 2007

DOI: 10.1002/0471141755.ph0313s39

Current Protocols in Pharmacology

Current Protocols in Pharmacology

How to Cite

Morgan-Linnell, S. K., Hiasa, H., Zechiedrich, L. and Nitiss, J. L. 2007. Assessing Sensitivity to Antibacterial Topoisomerase II Inhibitors. Current Protocols in Pharmacology. 39:3.13:3.13.1–3.13.26.

Author Information

  1. 1

    Baylor College of Medicine, Houston, Texas

  2. 2

    University of Minnesota Medical School-Twin Cities, Minneapolis, Minnesota

  3. 3

    St. Jude Children's Research Hospital, Memphis, Tennessee

Publication History

  1. Published Online: 1 DEC 2007
  2. Published Print: DEC 2007


Both prokaryotes and eukaryotes have two major classes of topoisomerases that make transient single- or double-strand cuts in DNA. While these enzymes play critical roles in cellular processes, they are also important targets of therapeutic agents. This unit describes assays to use in characterizing topoisomerase II-targeting agents in vitro and in bacterial cells. It provides protocols for characterizing the action of small molecules against bacterial type II topoisomerases in vitro and the in vivo effects of putative topoisomerase II-targeting antibiotics, as well as for measuring trapped enzyme/DNA covalent complexes, the major cytotoxic lesion induced by fluoroquinolones. Curr. Protoc. Pharmacol. 39:3.13.1-3.13.26. © 2007 by John Wiley & Sons, Inc.


  • topoisomerase;
  • gyrase;
  • antibiotic;
  • topoisomerase poison;
  • fluoroquinolone;
  • MIC;
  • MPC;
  • supercoil